Overview
Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to codeine and morphine. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of morphine. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as duloxetine and venlafaxine. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain. Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators. Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death. However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.
Indication
Tramadol is approved for the management of moderate to severe pain in adults. Tramadol is also used off-label in the treatment of premature ejaculation.
Associated Conditions
- Acute Pain
- Premature Ejaculation
- Severe Pain
- Acute, moderate, severe Pain
- Moderate Pain
Research Report
A Comprehensive Monograph on Tramadol (DrugBank ID: DB00193): Pharmacology, Clinical Use, and Safety Profile
Executive Summary
Tramadol is a centrally-acting synthetic analgesic used for the management of moderate to moderately severe pain in adults. Identified by DrugBank ID DB00193 and CAS Number 27203-92-5, it is classified as a small molecule drug. Its clinical utility is derived from a unique, dual mechanism of action that distinguishes it from traditional opioid analgesics. Tramadol functions as a weak agonist at the µ-opioid receptor and simultaneously inhibits the reuptake of serotonin and norepinephrine (SNRI), thereby modulating both opioid-mediated and monoaminergic descending pain pathways. This multimodal activity contributes to its efficacy across a spectrum of pain conditions, including neuropathic and chronic pain, and positions it as a Step 2 option on the World Health Organization's pain ladder.
The drug is administered as a racemic mixture of its (+)- and (-)-enantiomers, which act synergistically. The (+)-enantiomer and its primary active metabolite, O-desmethyltramadol (M1), are responsible for the µ-opioid receptor agonism and serotonin reuptake inhibition, while the (-)-enantiomer primarily inhibits norepinephrine reuptake. The conversion of tramadol to the more potent M1 metabolite is critically dependent on the cytochrome P450 2D6 (CYP2D6) enzyme. Genetic polymorphisms in CYP2D6 lead to significant inter-individual variability in analgesic response and toxicity risk. "Ultra-rapid metabolizers" are at high risk for opioid toxicity, including life-threatening respiratory depression, a fact highlighted in a specific FDA Black Box Warning that has led to contraindications in pediatric populations.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/08/07 | Not Applicable | Recruiting | National Cancer Institute, Egypt | ||
2025/07/15 | Not Applicable | Not yet recruiting | |||
2025/06/29 | Not Applicable | Completed | Syed Muhammad Abbas | ||
2025/02/05 | N/A | Recruiting | |||
2024/12/19 | Phase 4 | Active, not recruiting | medina medical center | ||
2024/12/11 | Not Applicable | Not yet recruiting | |||
2024/12/09 | Phase 3 | Recruiting | |||
2024/09/25 | Phase 4 | Not yet recruiting | |||
2024/09/19 | Phase 4 | Completed | Istanbul University - Cerrahpasa (IUC) | ||
2024/08/20 | Early Phase 1 | ENROLLING_BY_INVITATION |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Aidarex Pharmaceuticals LLC | 33261-483 | ORAL | 50 mg in 1 1 | 10/5/2012 | |
Aidarex Pharmaceuticals LLC | 33261-105 | ORAL | 50 mg in 1 1 | 10/22/2014 | |
NuCare Pharmaceuticals,Inc. | 68071-2648 | ORAL | 100 mg in 1 1 | 2/25/2022 | |
Medsource Pharmaceuticals | 45865-357 | ORAL | 50 mg in 1 1 | 7/19/2015 | |
Medsource Pharmaceuticals | 45865-170 | ORAL | 37.5 mg in 1 1 | 3/5/2024 | |
Lupin Pharmaceuticals, Inc. | 68180-697 | ORAL | 100 mg in 1 1 | 1/16/2024 | |
Galephar Pharmaceutical Research Inc. | 66277-239 | ORAL | 100 mg in 1 1 | 12/19/2022 | |
Quality Care Products, LLC | 55700-996 | ORAL | 100 mg in 1 1 | 2/24/2023 | |
Sun Pharmaceutical Industries, Inc. | 47335-860 | ORAL | 200 mg in 1 1 | 12/12/2023 | |
Palmetto Pharmaceuticals, Inc. | 68134-402 | ORAL | 5 mg in 1 mL | 12/21/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
SKUDEXA FILM-COATED TABLET 75 MG/25 MG | SIN15394P | TABLET, FILM COATED | 75 mg | 12/13/2017 | |
PENGESIC CAPSULE 50 mg | SIN10512P | CAPSULE | 50.00 mg | 12/8/1998 | |
ACUGESIC INJECTION 50 mg/ml (without preservative) | SIN10045P | INJECTION | 50 mg/ml | 9/23/1998 | |
MABRON INJECTION 100 mg/2 ml | SIN08740P | INJECTION | 100 mg/2 ml | 6/6/1996 | |
ULTRADOL F.C. TABLETS 37.5MG/325MG | SIN16498P | TABLET, FILM COATED | 37.5mg | 5/19/2022 | |
TRADOL INJECTION 50 mg/ml | SIN10057P | INJECTION | 50 mg/ml | 9/23/1998 | |
ACUGESIC CAPSULE 50 mg | SIN08953P | CAPSULE | 50 mg | 10/2/1996 | |
TRAMADOL STADA INJECTION 100 mg/2 ml | SIN08367P | INJECTION | 100 mg/2 ml | 10/2/1995 | |
TRACIDOL INJECTION 100mg/2ml | SIN15303P | INJECTION, SOLUTION | 100mg | 7/24/2017 | |
TRAMADOL 50 STADA CAPSULE 50 mg | SIN08365P | CAPSULE | 50 mg | 10/2/1995 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
TRAMED CAPSULES 50MG | N/A | N/A | N/A | 3/12/2025 | |
MODSENAL CAPSULES 50MG | N/A | N/A | N/A | 5/12/2025 | |
TRAMADOL 50 STADA CAP 50MG | N/A | N/A | N/A | 1/14/1997 | |
TRAMADOL 100 STADA SUPPOSITORIES 100MG | N/A | N/A | N/A | 9/15/1999 | |
TRAMO CAP 50MG | N/A | N/A | N/A | 12/7/1994 | |
TRAMADOL HYDROCHLORIDE TABLETS USP 50MG | N/A | N/A | N/A | 2/17/2021 |
TGA Drug Approvals
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
LUPIN-TRAMADOL/ACET | lupin pharma canada limited | 02407981 | Tablet - Oral | 37.50 MG | N/A |
PAT-TRAMADOL/ACET | 02389274 | Tablet - Oral | 37.5 MG | 8/14/2012 | |
TRIDURAL | Endo Operations Ltd. | 02296381 | Tablet (Extended-Release) - Oral | 100 MG | 8/14/2007 |
TRAMADOL/ACET | sanis health inc | 02426803 | Tablet - Oral | 37.5 MG | 7/25/2014 |
TARO-TRAMADOL ER | 02450445 | Tablet (Extended-Release) - Oral | 300 MG | 5/27/2016 | |
PRIVA-TRAMADOL/ACET | pharmapar inc | 02391554 | Tablet - Oral | 37.5 MG | 7/9/2013 |
MAR-TRAMADOL | marcan pharmaceuticals inc | 02480859 | Tablet - Oral | 50 MG | 7/18/2019 |
TRAMADOL-ACET | PRO DOC LIMITEE | 02417502 | Tablet - Oral | 37.5 MG | 2/3/2014 |
TRAMAPHEN-ODAN | odan laboratories ltd | 02388294 | Tablet - Oral | 37.5 MG | 9/5/2012 |
ZYTRAM XL | purdue pharma | 02286440 | Tablet (Extended-Release) - Oral | 300 MG | 12/7/2006 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.